Maxim raised the firm’s price target on Nutex Health (NUTX) to $50 from $45 and keeps a Buy rating on the shares. The company’s Q3 results topped estimates, with positive trends in metrics fueling its growth, the analyst tells investors in a research note. Maxim adds that the firm expects Nutex to generate $8.9M in operating cash per quarter through 2025 and believes that the company has sufficient capital to maintain current operations, even though it may raise capital to accelerate new hospital openings.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.